Autopsy report · NCT00077961
Rituximab Plus CAMPATH in Patients With Relapsed/Refractory Low-Grade or Follicular, CD20-positive, B-cell NHL
Cause of deathNo reason given
Life of this trial
- Registered 2 months after it had already started.
- 49 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1, Phase 2
- Sponsor
- Genzyme, a Sanofi Company
- Sponsor type
- Industry
- Conditions
- Non-Hodgkin's Lymphoma
- Interventions
- CAMPATH (alemtuzumab)
- Participants
- 49
- Sites
- 10
- Countries
- United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.